Clinical Trials
40 trialsTesting Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement
Eastern Cooperative Oncology Group
SuRage-EB
SRH Wald-Klinikum Gera GmbH
Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases
M.D. Anderson Cancer Center
UK-EnBiRiM
Pierre Fabre Ltd
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
Pfizer
BEPCOME-MB
UNICANCER
PORTSIDE
Pfizer
Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
H. Lee Moffitt Cancer Center and Research Institute
COLUMBUS
Pfizer
Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma
University of Kentucky
Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
M.D. Anderson Cancer Center
DETERMINE
University of Utah
ENCEFALO
Grupo Español Multidisciplinar de Melanoma
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
SWOG Cancer Research Network
EBIN
European Organisation for Research and Treatment of Cancer - EORTC
MK3475-C01
Sheba Medical Center
EBRAIN-MEL
Grupo Español Multidisciplinar de Melanoma
OCEANMIST
Pfizer
A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
Pfizer
Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors
Pfizer
BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation
Memorial Sloan Kettering Cancer Center
OCEANI
Pierre Fabre Medicament
SECOMBIT
Fondazione Melanoma Onlus
QUAD01
University of Pittsburgh
LOGIC-2
Pfizer
CELEBRATE
Peter MacCallum Cancer Centre, Australia
COLUMBUS-AD
Pierre Fabre Medicament
MEMBRAINS
Herlev Hospital
POLARIS
Pfizer
Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma
Pfizer
(Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma
Leiden University Medical Center
Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma
Pierre Fabre Medicament
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
Eli Lilly and Company
PREMIUM
Cambridge University Hospitals NHS Foundation Trust
IMMU-TARGET
University Hospital, Essen
BERING
Pierre Fabre Pharma GmbH
Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations
Jonsson Comprehensive Cancer Center
LOGIC
Array BioPharma
Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.
Array BioPharma